Show simple item record

dc.contributor.authorVollm, Birgit A.
dc.date.accessioned2017-09-20T16:00:17Z
dc.date.available2017-09-20T16:00:17Z
dc.date.issued2010
dc.identifier.citationLieb, K., Vollm, B. A. & Stoffers, J. (2010). Antipsychotics and borderline personality disorder: Authors' reply. The British Journal of Psychiatry, 196 (4), pp.332.
dc.identifier.other10.1192/bjp.196.4.332a
dc.identifier.urihttp://hdl.handle.net/20.500.12904/9438
dc.description.abstractReply by the current authors to the comments made by Jawad Adil (see record 2010-17019-018) on the original article (see record 2010-01466-002). We agree that the conclusions from National Institute for Health and Clinical Excellence (NICE) and our review are surprisingly different, considering similar literature search periods and widely similar inclusion criteria for primary studies. However, our scope was to assess and evaluate 'the mere evidence' of clinical outcomes. The NICE, in contrast, aims at the formulation of instructional recommendations for the British National Health Service. Indeed, there were and still are no Randomized Clinical Trials (RCTs) on quetiapine available. We agree that forest plotting would have contributed to a more immediate understanding of the evidence. However, may we refer you to the full Cochrane review which is to be published soon in the Cochrane Library. Forest plots will be provided there whenever appropriate. Finally, The American Psychiatric Association guidelines recommend low-dose antipsychotics in general, whereas our findings indicate that second-generation antipsychotics are supported by the current RCT evidence in particular. (PsycINFO Database Record (c) 2016 APA, all rights reserved)
dc.description.urihttps://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/authors-reply/66906ADD4D2BDBF19D76EC9A1FDE609E
dc.subjectDrug therapy
dc.subjectBorderline personality disorder
dc.titleAntipsychotics and borderline personality disorder: Authors' reply
dc.typeCommentary
html.description.abstractReply by the current authors to the comments made by Jawad Adil (see record 2010-17019-018) on the original article (see record 2010-01466-002). We agree that the conclusions from National Institute for Health and Clinical Excellence (NICE) and our review are surprisingly different, considering similar literature search periods and widely similar inclusion criteria for primary studies. However, our scope was to assess and evaluate 'the mere evidence' of clinical outcomes. The NICE, in contrast, aims at the formulation of instructional recommendations for the British National Health Service. Indeed, there were and still are no Randomized Clinical Trials (RCTs) on quetiapine available. We agree that forest plotting would have contributed to a more immediate understanding of the evidence. However, may we refer you to the full Cochrane review which is to be published soon in the Cochrane Library. Forest plots will be provided there whenever appropriate. Finally, The American Psychiatric Association guidelines recommend low-dose antipsychotics in general, whereas our findings indicate that second-generation antipsychotics are supported by the current RCT evidence in particular. (PsycINFO Database Record (c) 2016 APA, all rights reserved)


This item appears in the following Collection(s)

Show simple item record